Xenon Pharmaceuticals Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Xenon Pharmaceuticals Inc 公司

Xenon Pharmaceuticals Inc. 是一家总部位于加拿大的专注于神经科学的生物制药公司，致力于发现、开发和商业化治疗药物，以改善神经和精神疾病患者的生活。该公司正在推进一条新的产品线，以解决尚未得到满足的医疗需求领域，包括癫痫和抑郁症。Azetukalner 是该公司的主要 Kv7 通道开放剂，是最先进的、经过临床验证的钾通道调节剂，目前正处于多种适应症的后期临床开发阶段。Azetukalner 正在开发用于治疗癫痫，包括局灶性发作 (FOS) 和原发性全身性强直阵挛性发作 (PGTCS) 以及重度抑郁症 (MDD)。该公司正在评估针对各种适应症的多种针对 Kv7、Nav1.7 和 Nav1.1 的治疗候选药物。该公司正在与 Neurocrine Biosciences, Inc. 合作开发癫痫治疗方法。

Xenon Pharmaceuticals Inc简介



公司代码XENE

公司名称Xenon Pharmaceuticals Inc

上市日期Oct 17, 2014

CEOMr. Ian C. Mortimer, CPA

员工数量316

证券类型Ordinary Share

年结日Oct 17

公司地址3650 Gilmore Way

城市VANCOUVER

上市交易所NASDAQ Global Market Consolidated

国家Canada

邮编V5G 4W8

电话16044843300

网址https://www.xenon-pharma.com/

公司代码XENE

上市日期Oct 17, 2014

CEOMr. Ian C. Mortimer, CPA

Xenon Pharmaceuticals Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Ian C. Mortimer, CPA

President, Chief Executive Officer, Principal Operating Officer, Director

45.60K

--

Dr. Gary Patou, M.D.

Independent Director

28.48K

--

Ms. Dawn A. (Graham) Svoronos

Lead Independent Chairman of the Board

25.00K

--

Mr. Steven R. (Steve) Gannon, CPA

Independent Director

7.14K

-0.04%

Mr. Thomas J. (Tucker) Kelly, J.D.

Chief Financial Officer

--

Dr. Christopher Kenney, M.D.

Chief Medical Officer

--

Mr. Darren S. Cline

Chief Commercial Officer

--

Mr. Patrick Machado, J.D.

Independent Director

--

Dr. Gillian M. Cannon, Ph.D.

Independent Director

--

Mr. Justin Gover

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Ian C. Mortimer, CPA

President, Chief Executive Officer, Principal Operating Officer, Director

45.60K

--

Dr. Gary Patou, M.D.

Independent Director

28.48K

--

Ms. Dawn A. (Graham) Svoronos

Lead Independent Chairman of the Board

25.00K

--

Mr. Steven R. (Steve) Gannon, CPA

Independent Director

7.14K

-0.04%

Mr. Thomas J. (Tucker) Kelly, J.D.

Chief Financial Officer

--

Dr. Christopher Kenney, M.D.

Chief Medical Officer

--

收入明细

FY2025Q2

FY2025Q1

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

暂无数据

地区USD

名称

营收

占比

Canada

0.00

0.00%

业务

地区

暂无数据

股东统计

更新时间: 10月31日周五

持股股东

股东类型

持股股东

占比

Fidelity Management & Research Company LLC

8.29%

Avoro Capital Advisors LLC

6.99%

Driehaus Capital Management, LLC

5.61%

BlackRock Institutional Trust Company, N.A.

5.33%

Braidwell LP

4.67%

其他

69.12%

持股股东

占比

Fidelity Management & Research Company LLC

8.29%

Avoro Capital Advisors LLC

6.99%

Driehaus Capital Management, LLC

5.61%

BlackRock Institutional Trust Company, N.A.

5.33%

Braidwell LP

4.67%

其他

69.12%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

48.35%

Investment Advisor

33.63%

Hedge Fund

23.40%

Private Equity

1.90%

Research Firm

1.51%

Sovereign Wealth Fund

0.82%

Pension Fund

0.71%

Bank and Trust

0.34%

Individual Investor

0.14%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

446

85.67M

110.86%

-494.45K

2025Q2

418

85.39M

111.27%

+856.94K

2025Q1

434

79.94M

104.19%

-5.23M

2024Q4

434

79.81M

104.31%

-4.80M

2024Q3

425

77.49M

102.39%

-3.82M

2024Q2

431

76.92M

102.03%

-4.12M

2024Q1

421

76.68M

101.81%

-2.76M

2023Q4

404

75.13M

102.42%

+7.65M

2023Q3

386

64.60M

99.41%

-3.93M

2023Q2

377

64.25M

101.09%

-4.03M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Fidelity Management & Research Company LLC

6.40M

8.3%

+244.00K

+3.96%

Jun 30, 2025

Avoro Capital Advisors LLC

5.40M

7%

-341.67K

-5.95%

Jun 30, 2025

Driehaus Capital Management, LLC

4.34M

5.62%

-249.21K

-5.44%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.12M

5.34%

+3.47M

+534.85%

Jun 30, 2025

Braidwell LP

3.61M

4.68%

+895.15K

+33.03%

Jun 30, 2025

Janus Henderson Investors

3.58M

4.64%

+252.64K

+7.60%

Jun 30, 2025

Capital International Investors

3.18M

4.13%

+92.82K

+3.01%

Jun 30, 2025

Commodore Capital LP

3.02M

3.92%

+700.00K

+30.11%

Jun 30, 2025

Polar Capital LLP

2.70M

3.51%

+80.22K

+3.06%

Jun 30, 2025

Fidelity Institutional Asset Management

2.48M

3.22%

+352.87K

+16.57%

Jun 30, 2025

持股ETF



更新时间: 11月6日周四

机构名称

占比

iShares Neuroscience and Healthcare ETF

4.25%

ALPS Medical Breakthroughs ETF

1.85%

Goldman Sachs Future Health Care Equity ETF

1.03%

Virtus LifeSci Biotech Clinical Trials ETF

0.88%

First Trust Multi-Manager Small Cap Opportunities ETF

0.58%

JPMorgan Fundamental Data Science Small Core ETF

0.52%

iShares MSCI USA Small-Cap Min Vol Factor ETF

0.45%

JPMorgan Healthcare Leaders ETF

0.41%

ProShares Ultra Nasdaq Biotechnology

0.32%

Invesco Nasdaq Biotechnology ETF

0.31%

iShares Neuroscience and Healthcare ETF

占比4.25%

ALPS Medical Breakthroughs ETF

占比1.85%

Goldman Sachs Future Health Care Equity ETF

占比1.03%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.88%

First Trust Multi-Manager Small Cap Opportunities ETF

占比0.58%

JPMorgan Fundamental Data Science Small Core ETF

占比0.52%

iShares MSCI USA Small-Cap Min Vol Factor ETF

占比0.45%

JPMorgan Healthcare Leaders ETF

占比0.41%

ProShares Ultra Nasdaq Biotechnology

占比0.32%

Invesco Nasdaq Biotechnology ETF

占比0.31%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据